



COVID Therapeutics: Monoclonal Antibody Infusion Facility Checklist

Monoclonal antibodies are administered for the treatment of mild to moderate COVID-19 in patients who are at high risk to progress to severe COVID-19.

Patient identified as COVID positive via PCR or Antigen Test:

Confirm patient meets criteria to receive Monoclonal Antibody:

Adult Patient meets at least one of the following criteria:

- Has a body mass index (BMI) ≥ 35
- Has immunosuppressive disease
- Has chronic kidney disease
- Is currently receiving immunosuppressive treatment
- Has diabetes
- Is ≥ 65 years of age

OR

- Patient is ≥ 55 years of age **AND** has Cardiovascular disease **OR** Hypertension **OR**
- Chronic obstructive pulmonary disease/other chronic respiratory disease

Bamlanivimab is **not** authorized for use in patients:

- Who have been hospitalized due to COVID-19
- Who require oxygen therapy due to COVID-19
- Oxygen dependent patients who require an increase in oxygen flow rate due to COVID-19 complications

- Contact prescriber for order using Omnicare Intake/Prescriber Order specific for Bamlanivimab or Casirivimab/Imdevimab.
- Review monoclonal antibody therapy information, provide the “Fact Sheet for Patients, Parents and Caregivers”. Obtain patient/responsible party consent per facility protocol. Document in the patient’s medical record.
- Fax Omnicare Intake/Prescriber Order. Call IV pharmacy to inform of order and coordinate delivery.
- Establish patent vascular access device (short peripheral catheter is sufficient)
- Upon receipt of monoclonal antibody medication, refrigerate if not infusing immediately. Monoclonal antibodies have short stability and must be infused as soon as possible upon receipt of drug from pharmacy.
- Follow procedure 10.17 Administration of Bamlanivimab, or 10.18 Administration of Casirivimab/Imdevimab, for administration of monoclonal antibody.
- Report any adverse events following instructions in procedure.